- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07794826
Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients. SHINE-RLS (Super High-flux Dialysis Improves Neuro-symptoms and Efficacy in Restless Legs Syndrome) (SHINE-RLS)
Advancing Dialyzer Technology: Efficacy and Safety of Super High-Flux Hemodialysis in Maintenance Dialysis Patients
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Patients with end-stage kidney disease (ESKD) on regular high-flux hemodialysis (HD) often experience an accumulation of middle-molecule uremic toxins, which are linked to systemic inflammation and troubling symptoms such as restless legs syndrome (RLS), severe itching, and poor sleep quality. While traditional high-flux dialysis efficiently clears small molecules, its ability to remove larger middle-molecule toxins (like α1-microglobulin [α1-MG]) is limited. Current alternatives such as online hemodiafiltration (HDF) have limitations, highlighting the need for new treatment approaches. Super High-Flux Hemodialysis (SHFHD) offers enhanced clearance of these middle molecules while preserving serum albumin levels and maintaining patient safety.
In this study, the investigators evaluate the effectiveness and safety of SHFHD compared with high-flux HD in patients undergoing maintenance HD, focusing on α1-MG removal and its potential effect on RLS. The investigators also explore the multiple diverse effects of SHFHD on the changes of cardiovascular risk factors including bone turnover, mineral metabolism, vascular calcification, uremia, inflammation, immunity, metabolomics, nutrition, and gut microbial metabolites in dialysis patients.
It is to conduct a randomized, controlled, crossover trial with cross-over design at a dialysis unit of tertiary teaching hospital in Northern Taiwan. The investigators will stratify participants by baseline RLS. Participants will receive either SHFHD or high-flux HD for 12 weeks, followed by a 4-week washout and crossover. The study outcome measures are difference in change-from-baseline values of α1-MG reduction ratio, RLS severity (International Restless Legs Scale), albumin levels, clearance of β2-microglobulin, free light chains, inflammatory markers, pruritus scores, and quality of life. Safety will be assessed via albumin maintenance, adverse events, and hemodynamic stability.
This will be the first RCT directly evaluating SHFHD for α1-MG removal and RLS outcomes, addressing critical knowledge gaps and potentially informing new dialysis prescription strategies.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Wan-Chuan Tsai, M.D., Ph.D.
- Número de telefone: 1780 886-289667000
- E-mail: mkks618@gmail.com
Locais de estudo
-
-
Banciao Dist.
-
New Taipei City, Banciao Dist., Taiwan, 220
- Far Eastern Memorial Hospital
-
Contato:
- Wan-Chuan Tsai, M.D., Ph.D.
- Número de telefone: 1780 886-277281780
- E-mail: mkks618@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Diagnosis of Restless Legs Syndrome according to standard criteria.
- Age ≥ 20 years.
- Maintenance high-flux hemodialysis for ≥ 3 months.
- Stable vascular access (AV fistula or AV graft).
- Adequate dialysis delivery (URR ≥ 65% or Kt/V(daugirdes) ≥ 1.2).
- Sufficient iron stores (serum ferritin ≥ 200 ng/mL, TSAT ≥ 20%).
- Clinically stable condition for the past 4 weeks.
- Able and willing to comply with study protocol
Exclusion Criteria:
- Low-flux HD or temporary catheter use
- Serum albumin < 2.5 g/dL
- Recent hospitalization (within 4 weeks)
- Scheduled kidney transplantation
- Active malignancy or infection
- Pregnancy
- Any condition impairing protocol adherence
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Super High-Flux HD
Receives 12 weeks of Super High-Flux HD (Elisio™-HX)
|
Participants receive hemodialysis using a Type V super high-flux dialyzer (such as Elisio™-HX or Theranova) for 12 weeks to assess the clearance of middle-molecule uremic toxins and its effect on RLS symptoms.
|
|
Sem intervenção: High-Flux HD
Receives 12 weeks of High-Flux HD as usual care
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in α1-microglobulin (α1-MG) Reduction Ratio
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of α1-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit.
The primary outcome is the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in International Restless Legs Scale (IRLS) Score
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
IRLS score assesses the severity of Restless Legs Syndrome (ranging from 0 to 40, where higher scores indicate greater severity).
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Albumin Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Monitored to evaluate nutritional safety and albumin preservation during Super High-Flux HD compared to High-Flux HD.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pittsburgh Sleep Quality Index (PSQI) Score
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses sleep quality.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in 5-D Itch Scale Score
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses pruritus severity.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in health-related quality of life (EQ-5D-5L) Score
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Assesses quality of life.
Evaluated as the difference in score changes between the two treatment periods.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in β2-microglobulin [β2-MG] Reduction ratio
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio of β2-MG will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Kappa Free Light Chains Reduction ratio
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Lambda Free Light Chains Reduction ratio
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
The reduction ratio will be calculated as [({Pre-dialysis} - {Post-dialysis}) /{Pre-dialysis}] at each study visit and evaluated as the difference in the change-from-baseline reduction ratio between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum interleukin-6 (IL-6) Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum High-sensitivity C-reactive Protein (hs-CRP) Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum Indoxyl Sulfate Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
|
Change from Baseline in Pre-dialysis Serum P-cresol Sulfate Level
Prazo: Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Measured at each study visit.
Evaluated as the difference in the change from baseline between the Super High-Flux HD period and the High-Flux HD period.
|
Baseline, Week 4, Week 8, and Week 12 of each 12-week treatment period
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças do Sistema Nervoso
- Transtornos Mentais, Desordem Mental
- Processos Patológicos
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doença crônica
- Atributos da doença
- Distúrbios do Sono Vigília
- Insuficiência renal
- Distúrbios do Sono Intrínsecos
- Dissônias
- Parassonias
- Condições Patológicas, Sinais e Sintomas
- Insuficiência Renal Crônica
- Insuficiência Renal Crônica
- Síndrome das pernas inquietas
Outros números de identificação do estudo
- FEMH-IRB-TSAI2025
- FEMH-IIT-2026-01 (Número de outro subsídio/financiamento: Far Eastern Memorial Hospital)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .